NCT05554978

Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest

Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest: a Randomized, Double-blind, Placebo-controlled, Pilot Trial

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study investigates the efficacy of landiolol versus placebo in patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (electrical storm).

Detailed description

The use of beta-blockers in OHCA patients with refractory VF could potentially reverse the unwanted beta-1-mediated effects of endogenous and exogenous epinephrine (proarrhythmic effect), which could in turn lead to a shorter time until return of spontaneous circulation (ROSC). This is a prospective, double-blind, randomized placebo-controlled pilot trial. The investigators consider this a pilot trial, as this is the first prospective trial evaluating the use of beta-blockade in cardiac arrest.

Conditions

• Cardiac Arrest

Interventions

Type	Name	Description
DRUG	Landiolol	patient receives landiolol in addition to standard-of-care
DRUG	Sodium Chloride (NaCl) 0.9%	Placebo

Timeline

• Start date: 2021-03-03
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2022-09-26
• Last updated: 2023-03-17

Locations

1 site across 1 country: Austria